Clemens Kratochwil
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Overview
Clemens Kratochwil is a nuclear medicine physician at Heidelberg University Hospital, working within the NCT and DKFZ network. His specialisms are targeted alpha therapy, PSMA radioligands and dosimetry in prostate cancer. He reported the first patients treated with actinium-225 PSMA therapy, published in the Journal of Nuclear Medicine as 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. That first clinical experience launched the alpha-emitter era in prostate cancer, and he continues to work on actinium-225 PSMA agents and their dosimetry. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer | Journal of Nuclear Medicine | 2016 |
Similar pages
not linked directly; found by shared links- PersonUwe Haberkorn
Shares 177Lu-PSMA-617 then 225Ac-PSMA rescue therapy, 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer, Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, Targeted alpha therapy.
- TrialAlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
Shares Actinium-225 PSMA agents, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, Targeted alpha therapy.
- PairingBeta radioligand → alpha radioligand
Shares 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer, Actinium-225 PSMA agents, Targeted alpha therapy, Actinium-225.
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Actinium-225 PSMA agents, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Targeted alpha therapy, Actinium-225.
- PersonFrederik Giesel
Shares Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, European Association of Nuclear Medicine.
- Key paperPhase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC
Shares Actinium-225 PSMA agents, PSMA, Targeted alpha therapy, Actinium-225.
- CompanyConvergent Therapeutics
Shares PSMA, Targeted alpha therapy, Actinium-225, Prostate cancer.